覃桥莉,岑 朝,姚享章

胃癌是全球常见的恶性肿瘤之一，其发病率和死亡率均排在我国的前五。早期诊断和有效的生物标志物对于改善胃癌患者的预后尤为重要。近年以来，炎症标志物（血小板淋巴细胞比值PLR、中性粒细胞淋巴细胞比值NLR）、幽门螺杆菌（Hp）感染及新型生物标志物（如半胱氨酸蛋白酶抑制剂CST4）在胃癌发生、发展及预后中的作用备受关注。本文系统综述上述指标的生物学特性、在胃癌中的研究进展及临床应用价值，旨在为胃癌早期的诊断、个体化治疗和预后评估提供参考。

血小板淋巴细胞比值（PLR）、中性粒细胞淋巴细胞比值（NLR）；幽门螺杆菌（Hp）；半胱氨酸蛋白酶抑制剂S（CST4）；胃癌

[1] Filho A M,Laversanne M,Ferlay J,et al.The GLOBOCAN 2022 cancer estimates:Data sources,methods,and a snapshot of the cancer burden worldwide[J].Int J Cancer,2025,156(7):1336-1346. [2] 胡泽瑞,朱小琼,葛王舒琦,等.2022年全球及中国胃癌发病率和死亡率分析[J].海军军医大学学报:1-9. [3] Malfertheiner P,Megraud F,Rokkas T,et al.Management of Helicobacter pylori infection:the Maastricht VI/Florence consensus report[J]. Gut,2022. [4] 武国兵,程晓龙,于潇,等.幽门螺杆菌相关性慢性萎缩性胃炎与胃癌关系的研究进展[J].协和医学杂志,2023,14(02):339-345. [5] Li Y,Choi H,Leung K,et al.Global prevalence of Helicobacter pylori infection between 1980 and 2022:a systematic review and meta-analysis[J].Lancet Gastroenterol Hepatol,2023,8(6):553-564. [6] 雷瑚仪.门螺杆菌感染在特发性血小板减少性紫癜发病中作用及机制研究[D].南方医科大学,2022.10.27003/d.cnki. gojyu.2022.000320. [7] Yu Z,Chen J,Chen M,et al.Analysis between Helicobacter pylori infection and hepatobiliary diseases[J].Front Cell Infect Microbiol, 2025,15:1477699. [8] Gaonkar A,Zahiruddin Q S,Shabil M,et al.Association of Helicobacter pylori Infection and Risk of Dyslipidemia:A Systematic Review and Meta-Analysis[J].JGH Open,2025,9(3):e70128. [9] 周显祝.幽门螺杆菌家庭感染现状调查及胃癌筛查模式对照研究[D].中国人民解放军海军军医大学,2024.10.26998/d.cnki. gjuyu.2024.000005. [10] Ford A C,Yuan Y,Forman D,et al.Helicobacter pylori eradication for the prevention of gastric neoplasia[J].Cochrane Database Syst Rev,2020,7(7):CD5583. [11] Helicobacter Pylori Study Group Chinese Society Of Gastroenterology.2022中国幽门螺杆菌感染治疗指南[J].胃肠病学, 2022,27(03):150-162. [12] Robinson K,Atherton J C.The Spectrum of Helicobacter-Mediated Diseases[J].Annu Rev Pathol,2021,16:123-144. [13] Alavi Rostami S F,Khaledi M,Dalilian F,et al.Vacuolating Cytotoxin A(VacA)and Extracellular Vesicles in Helicobacter pylori:Two Key Arms in Disease Development[J].Iran J Pathol,2025,20(1):1-17. [14] 薄威.幽门螺杆菌vacA基因型与胃黏膜肠上皮化生关系[D].沈阳医学院,2017. [15] Xiao S,Shen Y,Zhang M,et al.VacA promotes pyroptosis via TNFAIP3/TRAF1 signaling to induce onset of atrophic gastritis[J]. Microbiol Res,2025,296:128142. [16] 周震,叶冠男,彭进,等.Wnt3､β-catenin､MMP-7在胃癌和癌前病变中的表达及其与幽门螺杆菌感染的相关性[J].中南大学学报(医学版),2021,46(06):575-582. [17] Choi M S,Ze E Y,Park J Y,et al.Helicobacter pylori-derived outer membrane vesicles stimulate interleukin 8 secretion through nuclear factor kappa B activation[J].Korean J Intern Med,2021,36(4):854-867. [18] Yeh J,Tsai S,Wu D,et al.P-selectin-dependent platelet aggregation and apoptosis may explain the decrease in platelet count during Helicobacter pylori infection[J].Blood,2010,115(21):4247-4253. [19] 张兵萍,刘蓉.慢性胃炎患者外周血血小板计数､血小板/淋巴细胞之值与幽门螺杆菌感染之间的关系探讨[J].血栓与止血学, 2021,27(06):986-987. [20] 杨少志,张玉树,程秋晨,等.幽门螺杆菌感染与新型炎症指标的相关性研究[J].现代消化及介入诊疗,2024,29(03):339-342. [21] Dvorak H F.Tumors:wounds that do not heal-redux[J].Cancer Immunol Res,2015,3(1):1-11. [22] Singh N,Baby D,Rajguru J P,et al.Inflammation and cancer[J].Ann Afr Med,2019,18(3):121-126. [23] 胡文庆.基于胃癌细胞及其肿瘤微环境中关键分子的研究[D].山西医科大学,2014. [24] Xiong S,Dong L,Cheng L.Neutrophils in cancer carcinogenesis and metastasis[J].J Hematol Oncol,2021,14(1):173. [25] Wu L,Saxena S,Singh R K.Neutrophils in the Tumor Microenvironment[J].Adv Exp Med Biol,2020,1224:1-20. [26] Christoffersson G,VågesjöE,Vandooren J,et al.VEGF-A recruits a proangiogenic MMP-9-delivering neutrophil subset that induces angiogenesis in transplanted hypoxic tissue[J].Blood,2012,120(23):4653-4662. [27] Singhal S,Bhojnagarwala P S,O'Brien S,et al.Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer[J].Cancer Cell,2016,30(1):120-135. [28] 张烨晟,杨易静,黄依雯,等.肿瘤微环境免疫细胞调节肿瘤细胞耐药性的研究进展[J].上海交通大学学报(医学版),2024, 44(07):830-838. [29] 韩忠丽,李凯.肿瘤微环境免疫细胞在胆管癌发生发展中作用的研究进展[J].内蒙古医科大学学报,2025,47(01):84-88. [30] Rodriguez P C,Ernstoff M S,Hernandez C,et al.Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes[J].Cancer Res,2009,69(4):1553-1560. [31] Gremmel T,Frelinger A L R,Michelson A D.Platelet Physiology[J].Semin Thromb Hemost,2024,50(8):1173-1186. [32] Ward Y,Lake R,Faraji F,et al.Platelets Promote Metastasis via Binding Tumor CD97 Leading to Bidirectional Signaling that Coordinates Transendothelial Migration[J].Cell Rep,2018,23(3):808-822. [33] Schlesinger M.Role of platelets and platelet receptors in cancer metastasis[J].J Hematol Oncol,2018,11(1):125. [34] Hou J,Karin M,Sun B.Targeting cancer-promoting inflammation-have anti-inflammatory therapies come of age?[J].Nat Rev Clin Oncol,2021,18(5):261-279. [35] 袁木发,王捷鹏,费素娟.外周血NLR､PLR､MLR和CEA对胃癌的诊断价值[J].江苏医药,2022,48(01):40-44. [36] Nguyen M L T,Pham C,Le Q V,et al.The diagnostic and prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio on gastric cancer patients[J].Medicine(Baltimore),2023,102(31):e34357. [37] 吴阳,唐凤英,张伟,等.血清NLR､PLR､AFP在老年未分化型早期胃癌患者中的预测价值及其临床意义[J].现代生物医学进展,2024,24(14):2772-2775. [38] 党永林,秦静,刘建山.炎性指标NLR､PLR联合肿瘤标志物在胃癌诊断中的应用价值[J].吉林医学,2025,46(02):264-267. [39] FonovićM,Turk B.Cysteine cathepsins and extracellular matrix degradation[J].Biochim Biophys Acta,2014,1840(8):2560-2570. [40] Gocheva V,Joyce J A.Cysteine cathepsins and the cutting edge of cancer invasion[J].Cell Cycle,2007,6(1):60-64. [41] Anastasi A,Brown M A,Kembhavi A A,et al.Cystatin,a protein inhibitor of cysteine proteinases.Improved purification from egg white,characterization,and detection in chicken serum[J].Biochem J,1983,211(1):129-138. [42] Abrahamson M,Alvarez-Fernandez M,Nathanson C.Cystatins[J].Biochem Soc Symp,2003(70):179-199. [43] Breznik B,MitrovićA,T Lah T,et al.Cystatins in cancer progression:More than just cathepsin inhibitors[J].Biochimie,2019, 166:233-250. [44] 侯健.CST4对人类胃癌SGC-7901细胞增殖､迁移和侵袭的影响及其作用机制[D].锦州医科大学,2024.10.27812/d.cnki. glnyx.2024.000742. [45] 宋正宇,郭嘉仪,张海平,等.食管鳞状细胞癌组织中CST4､VEGF-A表达与病理特征及预后的关系[J].医学研究杂志, 2024,53(11):51-56. [46] Gu C,Chen S,Huang L,et al.Serum Cystatin S(CST4):A Novel Prognostic Marker for Gastric Cancer[J].Clin Med Insights Oncol, 2025,19:1383432364. [47] Huang M,Yang Z,Ren J,et al.The Diagnosis Significance of Serum Cysteine Protease Inhibitors(CST4)in Colorectal Cancer[J].Technol Cancer Res Treat,2023,22:2071061176. [48] Zhang Y Q,Zhang J J,Song H J,et al.Overexpression of CST4 promotes gastric cancer aggressiveness by activating the ELFN2 signaling pathway[J].Am J Cancer Res,2017,7(11):2290-2304. [49] Chen Y,Li B,Wang J,et al.Investigating the prognostic and predictive value of the type II cystatin genes in gastric cancer[J].BMC Cancer,2023,23(1):1122. [50] Dou Y,Lv Y,Zhou X,et al.Antibody-sandwich ELISA analysis of a novel blood biomarker of CST4 in gastrointestinal cancers[J].Onco Targets Ther,2018,11:1743-1756. [51] 金水,王瑞,张丹丹,等.CST4､HP抗体分型及HER2在胃癌中的表达及其诊断价值[J].安徽医科大学学报,2024,59(12):2229-2236.

点击下载PDF